Article Information
History
- August 4, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Simone Lanini1,
- Stefano Milleri2,
- Emanuele Andreano3,
- Sarah Nosari4,
- Ida Paciello3,
- Giulia Piccini5,
- Alessandra Gentili7,
- Adhuna Phogat8,
- Inesa Hyseni5,6,
- Margherita Leonardi5,6,
- Alessandro Torelli5,
- Emanuele Montomoli5,6,10,
- Andrea Paolini8,9,
- Andrea Frosini8,
- Andrea Antinori1,
- Emanuele Nicastri1,
- Enrico Girardi1,
- Maria Maddalena Plazzi1,
- Giuseppe Ippolito1,
- Francesco Vaia1,
- Giovanni Della Cioppa11 and
- Rino Rappuoli3,12,*
- 1Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani – IRCCS, Rome, Italy
- 2Centro Ricerche Cliniche di Verona, University and Hospital Trust of Verona, Verona, Italy
- 3Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy
- 4AchilleS Vaccine, Siena, Italy
- 5VisMederi S.r.l, Siena, Italy
- 6VisMederi Research S.r.l, Siena, Italy
- 7CROss Research, Mendrisio, Switzerland
- 8Fondazione Toscana Life Sciences, Siena, Italy
- 9Toscana Life Sciences Sviluppo, Siena, Italy
- 10Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy
- 11Clinical R&D Consultants, Rome, Italy
- 12Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy
- ↵*Correspondence to Dr. Rino Rappuoli, Email: rino.r.rappuoli{at}gsk.com